Forbes included Israeli pharmaceutical firm Teva on its ranking of 130 “global superstars.” Ynet reported Monday that the Forbes shortlist, a lead-up to its annual “Global 2,000” ranking, is based on a combination of the firms’ sales, profits, assets and market value. In 2006, Teva registered $8.41 billion in sales, $55 million in profits, $20.47 billion in assets and a market value of $26.91
billion.
Support the Jewish Telegraphic Agency
Help ensure Jewish news remains accessible to all. Your donation to the Jewish Telegraphic Agency powers the trusted journalism that has connected Jewish communities worldwide for more than 100 years. With your help, JTA can continue to deliver vital news and insights. Donate today.
